• Police seek suspects in deadly birthday party shooting
  • Lawmakers launch inquires into U.S. boat strike
  • Nov. 29, 2025, 10:07 PM EST / Updated Nov. 30, 2025,…
  • Mark Kelly says troops ‘can tell’ what orders…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

Theo Von slams DHS for using his clip in agency post

admin - Latest News - September 26, 2025
admin
31 views 7 secs 0 Comments



Theo Von slams DHS for using his clip in agency post



Source link

TAGS:
PREVIOUS
Trump announces 100% tariffs of some pharmaceuticals
NEXT
Sept. 26, 2025, 11:24 AM EDTBy Rob Wile and Steve KopackAnalysts are already warning that U.S. consumers could see higher prices due to new tariffs President Donald Trump plans to impose on drug product imports as soon as next week.But a series of exemptions may blunt the ultimate impact. In a Truth Social post late Thursday, Trump said that any branded or patented pharmaceutical products brought into the U.S. would face a 100% tariff starting Oct. 1.U.S. imports of pharmaceuticals totaled about $213 billion in 2024, a threefold increase from a decade earlier, according to data from the United Nations Comtrade Database.With Asia alone accounting for just over 20% of those imports by value, U.S. consumers could see a “meaningful commercial hit,” Louise Loo, head of Asia economics at Oxford Economics research group, said in a note to clients. Previous studies have shown that U.S. annual spending per capita on prescription drugs is about double the rest of the developed world. In July, Trump announced a plan to “get Americans the best prices in the world for prescription drugs” that involved asking major drugmakers to match low prices they offer elsewhere in the world. However, it is not clear what actions the pharma firms have taken to begin addressing that demand. The pharmaceutical industry is already warning that the new tariffs could derail further drug development while also raising prices. “Every dollar spent on tariffs is a dollar that cannot be invested in American manufacturing or the development of future treatments and cures,” Alex Schriver, senior vice president for PhRMA, the drug industry’s primary lobbying group, said in a statement. “Medicines have historically been exempt from tariffs because they raise costs and could lead to shortages.”Despite those warnings, a significant share of drug products could wind up being exempted from the new import duties. The tariffs do not appear to apply to so-called generic drugs, which account for 9 out of 10 prescriptions filled in the U.S., according to the Food and Drug Administration. The White House did not immediately respond to a request to confirm the exemption for generics, but assuming they will remain tariff-free, the impact to consumers could be more limited than feared. Trump also specified that any drug companies that currently have, or have committed to building, U.S.-based drug-making facilities would be exempted from tariffs. That’s a category that includes numerous major drugmakers. “Many pharmaceutical companies have facilities in the U.S., so it may be relatively easy to superficially expand those facilities to avoid tariffs being applied,” Paul Donovan, chief global economist at UBS Global Wealth Management, wrote in a note to clients. Analysts at JPMorgan agreed: “While there remains very limited details, we note that this will likely lead to a majority of pharma products being excluded from any tariffs” because most major companies have recently increased or have started to increase their U.S. manufacturing facilities.On the White House website, the administration maintains a “running list of new U.S. investment” from private companies. At least 15 pharmaceutical or drug makers are listed with investments ranging from new manufacturing facilities, tens of billions in expanded U.S. production and increased R&D spending. Many of those announcements would appear to meet the requirements laid out by Trump to avoid the new tariff.Two major European drugmakers, Roche and Novartis, said in statements that they expected little to no impact from the newly announced duties. “We are working to ensure that all major Novartis medicines for U.S. patients are manufactured in the U.S.,” Novartis said in a statement. “The announced 100% tariff should not have an impact.” Roche pointed to ongoing factory construction in the U.S., with multiple sites being expanded and upgraded in Kentucky, Indiana, New Jersey and California.Trump has signaled since at least April that drug imports would face tariffs. In anticipation, major drugmakers have indicated they have been stockpiling supplies, analysts said. As a result, consumers are unlikely to feel immediate effects even though the tariffs are set to kick in next week. “We think there may have been significant inventory accumulation this year,” Neil Shearing, group chief economist with Capital Economics, said in a note. This summer, Trump placed a maximum 15% tariff on most pharmaceuticals coming in from the European Union, which accounts for 60% of drugs imported by the U.S. E.U. officials believe that this agreement will shield it from the 100% duties, though they said they could not be certain. “This clear all-inclusive 15% tariff ceiling for E.U. exports represents an insurance policy that no higher tariffs will emerge for European economic operators,” a European Commission spokesperson told NBC News on Friday.Ireland’s deputy prime minister, Simon Harris, who also acts as trade minister, said his country is “studying the impact of this announcement” but added that he believed the 15% cap on pharma tariffs remained in place. Ireland alone accounts for 24% of pharma imports to the U.S.Rob WileRob Wile is a Pulitzer Prize-winning journalist covering breaking business stories for NBCNews.com.Steve KopackSteve Kopack is a senior reporter at NBC News covering business and the economy.
Related Post
November 2, 2025
Savewith a NBCUniversal ProfileCreate your free profile or log in to save this articleNov. 2, 2025, 9:00 AM ESTBy Ben KamisarThe share of registered voters with positive views of capitalism has dropped under 50% for the first time in seven years of NBC News polling on the issue — a shift that comes as some democratic socialists, like New York mayoral hopeful Zohran Mamdani, gain prominence in the Democratic Party.Overall, 44% of registered voters say they have a positive view of capitalism, while 28% view it negatively. That’s a dip from how the economic system had been viewed in previous polls, which showed slim majorities viewing capitalism positively.There’s a stark partisan difference in views on capitalism, a trend that also plays out in various demographics more likely to identify with either party. Two-thirds of Republicans view capitalism positively, compared to 44% of independents and 25% of Democrats. Just 12% of Republicans view capitalism negatively, compared to 28% of independents and 45% of Democrats.Notably, 39% of Democrats viewed capitalism positively in September 2024, while 34% viewed it negatively then — a 5-point net-positive rating, compared to a 20-point net-negative rating among Democrats now.Voters under the age of 35 also swung heavily toward more negative views of capitalism over the last year, while Hispanic voters also swung in the same direction and are now effectively split on the economic system.Meanwhile, views of socialism have stayed more stable. Now, 49% of registered voters view it negatively — a slight decline from past measurements, which bounced between 50% and 55%. And 18% view socialism positively, right in line with how voters have felt each time the question has been asked since 2018.Under the hood, the trends look similar to the movement on capitalism, just in reverse.Last September, 34% of Democrats viewed socialism positively and 29% viewed it negatively. Now, a similar 35% of Democrats view socialism positively, but 20% view it negatively.While Hispanic voters soured a bit on capitalism in the poll, their views on socialism didn’t move in the same way. Hispanic voters viewed socialism negatively by a 29-point margin in 2024. Now, it’s a 24-point margin.Views on capitalism and socialism, particularly among Democrats, are evolving as Mamdani and other self-described democratic socialists like Sen. Bernie Sanders, I-Vt., and Rep. Alexandria Ocasio-Cortez, D-N.Y., have become increasingly powerful in their party, barnstorming the country and commanding a vocal constituency.Mamdani, having come up in politics as a democratic socialist and still leaning into that identity, could be on the precipice of winning arguably the largest office in the movement’s history.“I call myself a democratic socialist, in many ways inspired by the words of Dr. King from decades ago. ‘Call it democracy, or call it democratic socialism, there has to be a better distribution of wealth for all of God’s children in this country,’” Mamdani told NBC News’ “Meet the Press” this summer.Mamdani’s top opponent, Andrew Cuomo, the former Democratic governor of New York, has used that affiliation as a cudgel. Before and after Mamdani defeated him in the June Democratic primary, Cuomo has called Mamdani a socialist, not a Democrat, and warned that his policies will bankrupt the city.“I am the Democrat. He is a socialist. New York cannot survive as a socialist economy,” Cuomo told Fox News last week.Though Mamdani is running for a municipal post, the campaign’s national prominence in the nation’s largest city means that about two-thirds of registered voters nationally already feel they know enough about him to register an opinion on him.Overall, 22% of registered voters view Mamdani positively, while 32% view him negatively and 14% have a neutral view. Another 32% either aren’t sure or don’t know enough to rate him.Virtually every Republican who knows enough about Mamdani to rate him views him negatively, while Mamdani fares much better among Democrats: 44% view him positively and 10% view him negatively. Among independents, 16% view him positively and 25% view him negatively.The NBC News poll surveyed 1,000 registered voters from Oct. 24-28 via a mix of telephone interviews and an online survey sent via text message. The margin of error is plus or minus 3.1 percentage points.Ben KamisarBen Kamisar is a national political reporter for NBC News
November 20, 2025
Photo captures skydiver appearing to fall from the Sun
September 21, 2025
Charlie Kirk assassin’s alleged gun was powerful, vintage and hard to trace
November 5, 2025
NTSB says footage shows left engine detaching from wing during takeoff before deadly UPS crash
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved